Trial Parameters
Brief Summary
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
Eligibility Criteria
Inclusion Criteria: 1. Expected survival of at least 3 months; 2. Subjects should have measurable disease that meets the IMWG 2016 criteria; 3. Previously received at least two lines of prior anti-myeloma therapy ； 4. Relapse , failure to achieve at least a minimal response, or disease progression after the last treatment ； 5. BCMA positive； 6. ECOG score 0-1； 7. No severe impairment or suppression of liver, kidney, coagulation, bone marrow, or lung function. Exclusion Criteria: 1. Pregnant or breastfeeding women; 2. History of other malignant tumors; 3. Active autoimmune diseases requiring immunotherapy; 4. Previously received allogeneic stem cell transplantation; 5. Previous use of CAR-T cells or other genetically modified T cell therapies; 6. Previously received targeted BCMA therapy; 7. Severe cardiovascular disease; 8. Active infection; 9. Positive virology test; 10. Clinically significant central nervous system (CNS) diseases or pathological changes.